• 1
    Kirkwood JM,Agarwala SS. Systemic cytotoxic and biologic therapy melanoma. In: DeVita VTJr,Hellman S,Rosenberg SA, eds. Principles and Practice of Oncology. Philadelphia, Pa: Lippincott Williams and Wilkins; 1993: 116.
  • 2
    Middleton MR,Grob JJ,Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18: 158166.
  • 3
    Chapman PB,Einhorn LH,Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999; 17: 27452751.
  • 4
    Falkson CI,Ibrahim J,Kirkwood JM,Coates AS,Atkins MB,Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998; 16: 17431751.
  • 5
    Rusthoven JJ,Quirt IC,Iscoe NA, et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996; 14: 20832090.
  • 6
    Agarwala SS,Ferri W,Gooding W,Kirkwood JM. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer. 1999; 85: 19791984.
  • 7
    Atkins MB,Lotze MT,Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17: 21052116.
  • 8
    Stevens MF,Hickman JA,Stone R, et al. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl- 3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-1, a novel broad-spectrum antitumor agent. J Med Chem. 1984; 27: 196201.
  • 9
    Stevens MF,Hickman JA,Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-1 (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987; 47: 58465852.
  • 10
    Agarwala SS,Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000; 5: 144151.
  • 11
    Gibson NW,Hickman JA,Erickson LC. DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one. Cancer Res. 1984; 44: 17721775.
  • 12
    Hartley JA,Gibson NW,Kohn KW,Mattes WB. DNA sequence selectivity of guanine-N7 alkylation by 3 antitumor chloroethylating agents. Cancer Res. 1986; 46(4 pt 2): 19431947.
  • 13
    Tsang LL,Quarterman CP,Gescher A,Slack JA. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol. 1991; 27: 342346.
  • 14
    Gerson SL,Spiro TP,Reidenberg P, et al. Rapid depletion of O6-alkyguanine DNA alkytransferase with twice daily oral temozolomide (SCH 52365) in patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol. 1996; 14: 178. Abstract 366.
  • 15
    Tolcher AW,Gerson SL,Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003; 88: 10041011.
  • 16
    Brock CS,Newlands ES,Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998; 58: 43634367.
  • 17
    Figueroa J,Tolcher A,Denis L, et al. Protracted cyclic administration of temozolomide is feasible: a phase I, pharmacokinetic and pharmacodynamic study. Proc Am Soc Clin Oncol. 2000: 19. Abstract 868.
  • 18
    Eton O,Legha SS,Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002; 20: 20452052.
  • 19
    Atkins MB,Lee S,Flaherty LE,Sosman JA,Sondak VK,Kirkwood JM. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 708. Abstract 2874.
  • 20
    Keilholz U,Punt CJ,Gore M, et al. Dacarbazine, cisplatin, and IFN-a2b with or without IL-2 in advanced melanoma: final analysis of EORTC randomized phase III trial 18951. Proc Am Soc Clin Oncol. 2003; 22. Abstract 2848.
  • 21
    Del Vecchio M,Bajetta E,Vitali M, et al. Multicenter phase III randomized trial of cisplatin, vindesine, and decarbazine (CVD) versus CVD plus subcutaneous (SC) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma patients (PTS). Proc Am Soc Clin Oncol. 2003; 22. Abstract 2849.
  • 22
    Ives NJStowe RL,Lorigan P,Wheatley K. Biochemotherapy versus chemotherapy for metastatic malignant melanoma: a meta-analysis of the randomised trials [abstract]. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 2007; 2007; 25(18S). Abstract 8544.
  • 23
    Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 24
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 25
    Balch CM,Buzaid AC,Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 36353648.
  • 26
    Tarhini AA,Kirkwood JM,Gooding WE,Cai C,Agarwala SS. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol. 2007; 25: 38023807.
  • 27
    McDermott DF,Regan MM,Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005; 23: 133141.
  • 28
    Korn EL,Arbuck SG,Pluda JM,Simon R,Kaplan RS,Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 2001; 19: 265272.
  • 29
    Harrison BE,Johnson JL,Clough RW,Halperin EC. Selection of patients with melanoma brain metastases for aggressive treatment. Am J Clin Oncol. 2003; 26: 354357.
  • 30
    Amer MH,Al-Sarraf M,Baker LH,Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978; 42: 660668.
  • 31
    Patel JK,Didolkar MS,Pickren JW,Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978; 135: 807810.
  • 32
    Bullard DE,Cox EB,Seigler HF. Central nervous system metastases in malignant melanoma. Neurosurgery. 1981; 8: 2630.
  • 33
    Budman DR,Camacho E,Wittes RE. The current causes of death in patients with malignant melanoma. Eur J Cancer. 1978; 14: 327330.
  • 34
    Sampson JH,Carter JHJr,Friedman AH,Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998; 88: 1120.
  • 35
    Patchell RA,Tibbs PA,Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322: 494500.
  • 36
    Vecht CJ,Haaxma-Reiche H,Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993; 33: 583590.
  • 37
    Smalley SR,Laws ERJr,O'Fallon JR,Shaw EG,Schray MF. Resection for solitary brain metastasis. Role of adjuvant radiation and prognostic variables in 229 patients. J Neurosurg. 1992; 77: 531540.
  • 38
    Sause WT,Crowley JJ,Morantz R, et al. Solitary brain metastasis: results of an RTOG/SWOG protocol evaluation of surgery + RT versus RT alone. Am J Clin Oncol. 1990; 13: 427432.
  • 39
    Kondziolka D,Martin JJ,Flickinger JC, et al. Long-term survivors after gamma knife radiosurgery for brain metastases. Cancer. 2005; 104: 27842791.
  • 40
    Gaudy-Marqueste C,Regis JM,Muracciole X, et al. Gamma-knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys. 2006; 65: 809816.
  • 41
    Maker AV,Phan GQ,Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin-2: a phase I/II study. Ann Surg Oncol. 2005; 12: 10051016.